The PHASE3 trial for CagriSema (Cagrilintide B and Semaglutide I), investigating its efficacy in people with excess body weight, completed its primary data collection on October 30, 2024. This study, identified as NCT05567796, enrolled 3400 participants to evaluate weight loss compared to individual components and placebo.
Background
CagriSema is a combination investigational drug that includes cagrilintide and semaglutide. It is being developed for the treatment of obesity, a condition characterized by excess body weight. Semaglutide is a related drug that is already approved for weight management in certain populations.
Trial design
The study, designated as NCT05567796, is a PHASE3 trial with an enrollment of 3400 participants. The trial focuses on individuals with Obesity, aiming to assess how well CagriSema helps participants lose weight. Participants were randomized to receive one of four study medicines: CagriSema, cagrilintide, semaglutide, or a placebo.
What this means
The primary completion of this PHASE3 trial signifies that the main data collection period for CagriSema in participants with excess body weight has concluded. This milestone is a critical step in the drug's development pathway, as it precedes the analysis of the collected data to determine the efficacy and safety profile of CagriSema compared to its individual components and placebo. The results from this large-scale study will be crucial for understanding its potential role in obesity management.
Source
This information was sourced from ClinicalTrials.gov, documenting the primary completion status of trial NCT05567796, which was updated on October 30, 2024. Further details about the study are available on clinicaltrials.gov.